The CGT industry has experienced exponential growth in recent years, creating possibilities to cure the “incurable”.
Advancements in this space are affecting stakeholders across healthcare, as the industry looks to better adapt commercialization, P&MA, financing, and contracting systems.
Take a closer look at our insights and be the first to learn from our experts about how manufacturers, healthcare systems, and payers can grasp the opportunities and overcome the challenges present in this ever-evolving environment.
Cell & Gene Therapy: Curing the 'Incurable'
Until recently, there had been multiple breakthrough therapies for rare diseases but few cures.
We interviewed pharmaceutical Pricing & Market Access experts, Dirk Kars and Christian Schuler, to find out how P&MA hurdles can be overcome, facilitating better access to future cell and gene therapies.
Explore the Collection
Meet the Experts
Our experts are always happy to discuss your issue. Reach out, and we’ll connect you with a member of our team.